/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The investment giant is rumoured to be eyeing an exit with a 5x return, having taken the drugmaker from obscurity to a billion-dollar bidding war.
KKR is set to hit paydirt once again. And, this time around, the global investment firm could surpass its own Indian record.
Multiple news reports suggest that it is preparing the ground for an exit from JB Chemicals and Pharmaceuticals, which it acquired back in July 2020. The talks are reportedly at an advanced stage.
That investment of Rs 3,100 crore, for a 54% stake in the Mumbai-based drugmaker, is now worth well over Rs 16,000 crore, on the back of the over fivefold increase in the company’s market capitalization in the last four years—from Rs 5,740 crore to Rs …
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
Highlights from Saudi Arabia’s flagship FII conference, Tabby’s new valuation and UAE government bonds, among other updates.
Global investors are betting on Kerala’s healthcare boom. But it remains to be seen whether private capital can coexist with the state’s public ethos.
